Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Nat Biotechnol. 2020 Dec;38(12):1431-1440. doi: 10.1038/s41587-020-0572-6. Epub 2020 Jun 29.
N-Methyladenosine (mA) is the most widespread internal messenger RNA modification in humans. Despite recent progress in understanding the biological roles of mA, the inability to install mA site specifically in individual transcripts has hampered efforts to elucidate causal relationships between the presence of a specific mA and phenotypic outcomes. In the present study, we demonstrate that nucleus-localized dCas13 fusions with a truncated METTL3 methyltransferase domain and cytoplasm-localized fusions with a modified METTL3:METTL14 methyltransferase complex can direct site-specific mA incorporation in distinct cellular compartments, with the former fusion protein having particularly low off-target activity. Independent cellular assays across multiple sites confirm that this targeted RNA methylation (TRM) system mediates efficient mA installation in endogenous RNA transcripts with high specificity. Finally, we show that TRM can induce mA-mediated changes to transcript abundance and alternative splicing. These findings establish TRM as a tool for targeted epitranscriptome engineering that can reveal the effect of individual mA modifications and dissect their functional roles.
N6-甲基腺苷(m6A)是人类中分布最广泛的内部信使 RNA 修饰。尽管最近在理解 m6A 的生物学作用方面取得了进展,但由于无法在单个转录本中特异性地安装 m6A 位点,因此难以阐明特定 m6A 的存在与表型结果之间的因果关系。在本研究中,我们证明了定位于核内的 dCas13 融合蛋白与截断的 METTL3 甲基转移酶结构域以及定位于细胞质的融合蛋白与修饰的 METTL3:METTL14 甲基转移酶复合物可以在不同的细胞区室中指导特异性 m6A 掺入,前者融合蛋白的脱靶活性特别低。来自多个位点的独立细胞测定证实,这种靶向 RNA 甲基化(TRM)系统可以在高度特异性的内源性 RNA 转录本中有效地进行 m6A 安装。最后,我们表明 TRM 可以诱导 m6A 介导的转录物丰度和可变剪接的变化。这些发现确立了 TRM 作为靶向表转录组工程的工具,可揭示单个 m6A 修饰的作用并剖析其功能作用。